EUVIMEDEUVIMED entdecken
Crossref

Red blood cell membrane-camouflaged nanocarriers for the delivery of piperlongumine to treat triple-negative breast cancer

Chenxi Li iD, Jiaxin Zhang iD, Xianxian Yao, Yuxin Huang, Yichen Zhang, Wuli Yang iD

Biomedical Materials · 2025

DOI: 10.1088/1748-605x/add4da ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical Materials, 2025. Verfasst von Chenxi Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Molecular Engineering of Polymers and Department of Macromolecular Science, Fudan University, 220 Handan Road, Shanghai 20043…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Dioxolanes, Erythrocyte Membrane, Drug Carriers. Die Arbeit nennt 56 Literaturangaben. Gefördert von: Program of Shanghai Research Leader, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The application of the conventional drugs for triple-negative breast cancer (TNBC) treatment in chemotherapy is limited due to their intrinsic drawbacks such as short drug half-life, lack of tumor selectivity and systemic toxicity. Herein, an effective nanoparticle drug delivery system (NDDS) of red blood cell (RBC) membrane-camouflaged piperlongumine (PL)-loaded iron oxide (Fe 3 O 4 ) magnetic nanoparticles (Fe 3 O 4 -PL@RBC) was rationally designed as an effective drug delivery platform for in vivo TNBC treatment. The Fe 3 O 4 -PL@RBC showed considerable cytotoxicity against MDA-MB-231 cells, inducing intracellular accumulation of reactive oxygen species, mitochondrial dysfunction and apoptosis. Furthermore, transcriptomic analyses and western blotting analysis demonstrated that the Fe 3 O 4 -PL@RBC induced apoptosis through the inhibition of PI3K/AKT/mTOR pathway and downregulation of Bcl-2 protein. In MDA-MB-231 tumor models, the RBC membrane coating in Fe 3 O 4 -PL@RBC effectively prolonged the circulation time and sufficient enrichment at the tumor sites. And the Fe 3 O 4 -PL@RBC significantly inhibited tumor growth with good biosafety. This study provides guidance for the rational design of effective Fe 3 O 4 -based NDDS for TNBC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsDioxolanesErythrocyte MembraneDrug CarriersHumansFemaleApoptosisCell Line, TumorAnimalsMiceDrug Delivery SystemsReactive Oxygen SpeciesMagnetite NanoparticlesAntineoplastic AgentsMice, NudePiperidones

Stichwörter der Autor:innen

chemotherapynanoparticle-based drug delivery (NDDS)piperlongumine (PL)red blood cell membranetriple-negative breast cancer (TNBC)

Substanzen

piperlongumineDioxolanesDrug CarriersReactive Oxygen SpeciesMagnetite NanoparticlesAntineoplastic AgentsPiperidones

Autor:innen und Institutionen

  • State Key Laboratory of Molecular Engineering of Polymers and Department of Macromolecular Science, Fudan University, 220 Handan Road, Shanghai 200433, People's Republic of China.

ORCID-Profile: Chenxi Li, Jiaxin Zhang, Wuli Yang

Förderung

  • Program of Shanghai Research Leader
  • National Natural Science Foundation of China

Zitieren

APA

Li, C., Zhang, J., Yao, X., Huang, Y., Zhang, Y., & Yang, W. (2025). Red blood cell membrane-camouflaged nanocarriers for the delivery of piperlongumine to treat triple-negative breast cancer. Biomedical Materials. https://doi.org/10.1088/1748-605x/add4da

Vancouver

Li C, Zhang J, Yao X, Huang Y, Zhang Y, Yang W. Red blood cell membrane-camouflaged nanocarriers for the delivery of piperlongumine to treat triple-negative breast cancer. Biomedical Materials. 2025. doi:10.1088/1748-605x/add4da

BibTeX
@article{Li2025,
  author = {Li, Chenxi and Zhang, Jiaxin and Yao, Xianxian and Huang, Yuxin and Zhang, Yichen and Yang, Wuli},
  title = {Red blood cell membrane-camouflaged nanocarriers for the delivery of piperlongumine to treat triple-negative breast cancer},
  journal = {Biomedical Materials},
  year = {2025},
  doi = {10.1088/1748-605x/add4da}
}
Kostenlos starten →